Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Authors:
- Alessandra FabiAFAlessandra Fabi
- Michelangelo RussilloMRMichelangelo Russillo
- Gianluigi FerrettiGFGianluigi Ferretti
- Giulio MetroGMGiulio Metro
- Cecilia NisticòCNCecilia Nisticò
- Paola PapaldoPPPaola Papaldo
- Ferdinando De VitaFVFerdinando De Vita
- Giuliana D’auriaGDGiuliana D’auria
- Antonello VidiriAVAntonello Vidiri
- Diana GiannarelliDGDiana Giannarelli
- Francesco CognettiFCFrancesco Cognetti
Open Access
- 19 October 2012
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 482
Abstract
Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, no clinical data exist about combination of maintenance Bevacizumab (mBev) with HT.Keywords
This publication has 26 references indexed in Scilit:
- Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trialsJournal of Experimental & Clinical Cancer Research, 2011
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast CancerJournal of Clinical Oncology, 2011
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumabEuropean Journal of Cancer, 2008
- VEGF Inhibition and Renal Thrombotic MicroangiopathyNew England Journal of Medicine, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Rapid vascular regrowth in tumors after reversal of VEGF inhibitionJournal of Clinical Investigation, 2006
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971